“GAME-CHANGER”: COVID PILL 89% EFFECTIVE AGAINST SEVERE DISEASE, PFIZER SAYS

Fri 05 November 2021:

A clinical trial of Pfizer’s first pill to treat Covid-19 shown that it is highly effective, according to the company.

According to Pfizer, the medicine Paxlovid reduced the probability of hospitalization or death by 89 percent in adult Covid patients who were at high risk of developing severe illness.

“Today’s news is a real game-changer in the global efforts to halt the devastation of this pandemic,” said Pfizer CEO Albert Bourla.

“These data suggest that our oral antiviral candidate, if approved or authorized by regulatory authorities, has the potential to save patients’ lives, reduce the severity of Covid-19 infections, and eliminate up to nine out of 10 hospitalizations,” he added.

We’re proud to announce that our #COVID19 oral #antiviral candidate demonstrated significantly reduced risk of hospitalization or death in high-risk adults in new data.

If approved, it could help to lessen the impact of COVID-19 on patients & society: https://t.co/Ek33qj56HV pic.twitter.com/NKTzaOZBeJ

— Pfizer Inc. (@pfizer) November 5, 2021

The results of this mid-to-late-stage clinical trial are so promising, Pfizer has decided to stop recruiting new participants.

As part of its “rolling submission” for Emergency Use Authorization, it will send the data to the Food and Drug Administration as soon as possible.

Several companies are developing so-called oral antivirals, which would operate similarly to Tamiflu in preventing the condition from becoming severe.

Pfizer began working on its drug in March 2020.

_____________________________________________________________________________

FOLLOW INDEPENDENT PRESS:

TWITTER (CLICK HERE)
https://twitter.com/IpIndependent